Foresite Capital Management VI LLC — 13F Holdings & Portfolio
CIK 2013341 · latest 13F-HR filed 2026-08-14
Foresite Capital Management VI LLC manages $642.6M in 13F-reported U.S. long-equity assets across 23 reported positions as of its 2026-06-30 13F-HR filing. Its largest disclosed positions are CGON (26.20%), ALMS (18.60%), SPTX (6.02%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 8 new positions, exited 2, added to 10, and trimmed 2.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
SUITE PH1
WEST HOLLYWOOD, CA 90069
$642.6M
Long-equity book
23
Distinct positions
2026-06-30
Filed 2026-08-14
+8 / −2 / ↑10 / ↓2
vs 2026-03-31
| Name | Title / Status | Ownership | Type |
|---|
Top Adds (vs prior quarter)
- ALUMIS INC.$26.0M +27.7%
- Celldex Therapeutics, Inc.$22.7M +226.7%
- GH Research PLC$20.8M +469.9%
- CG Oncology, Inc.$18.0M +12.0%
- Jade Biosciences, Inc.$15.2M +338.2%
New Positions
- Seaport Therapeutics, Inc.$38.7M
- Parabilis Medicines, Inc.$27.3M
- Beam Therapeutics Inc.$11.3M
- ArriVent BioPharma, Inc.$10.5M
- Aura Biosciences, Inc.$9.5M
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | CG Oncology, Inc. | CGON | 156944100 | $168.4M | 26.20% | 2,369,574 | SH |
| 2 | ALUMIS INC. | ALMS | 022307102 | $119.5M | 18.60% | 4,247,670 | SH |
| 3 | Seaport Therapeutics, Inc. | SPTX | 81221K108 | $38.7M | 6.02% | 1,779,521 | SH |
| 4 | Denali Therapeutics Inc. | DNLI | 24823R105 | $35.9M | 5.59% | 1,396,771 | SH |
| 5 | Celldex Therapeutics, Inc. | CLDX | 15117B202 | $32.7M | 5.09% | 879,713 | SH |
| 6 | AGIOS PHARMACEUTICALS, INC. | AGIO | 00847X104 | $29.1M | 4.53% | 785,000 | SH |
| 7 | Corvus Pharmaceuticals, Inc. | CRVS | 221015100 | $27.4M | 4.26% | 1,831,233 | SH |
| 8 | Parabilis Medicines, Inc. | PBLS | 698955101 | $27.3M | 4.26% | 999,044 | SH |
| 9 | GH Research PLC | GHRS | G3855L106 | $25.3M | 3.93% | 940,493 | SH |
| 10 | Jade Biosciences, Inc. | JBIO | 008064206 | $19.7M | 3.07% | 886,667 | SH |
| 11 | Hinge Health, Inc. | HNGE | 433313103 | $18.3M | 2.85% | 220,400 | SH |
| 12 | Kymera Therapeutics, Inc. | KYMR | 501575104 | $16.8M | 2.61% | 146,332 | SH |
| 13 | AtaiBeckley Inc. | ATAI | 04650F101 | $14.5M | 2.26% | 2,750,000 | SH |
| 14 | Verastem, Inc. | VSTM | 92337C203 | $12.0M | 1.87% | 3,146,631 | SH |
| 15 | Beam Therapeutics Inc. | BEAM | 07373V105 | $11.3M | 1.76% | 330,000 | SH |
| 16 | Minerva Neurosciences, Inc. | NERV | 603380205 | $11.0M | 1.71% | 1,985,584 | SH |
| 17 | ArriVent BioPharma, Inc. | AVBP | 04272N102 | $10.5M | 1.63% | 301,341 | SH |
| 18 | Aura Biosciences, Inc. | AURA | 05153U107 | $9.5M | 1.47% | 1,333,334 | SH |
| 19 | Crinetics Pharmaceuticals, Inc. | CRNX | 22663K107 | $7.9M | 1.23% | 212,010 | SH |
| 20 | Research Alliance Corp III | RACC | G75226103 | $3.2M | 0.50% | 300,000 | SH |
| 21 | Zura Bio Ltd | ZURA | G9TY5A101 | $2.7M | 0.41% | 450,000 | SH |
| 22 | Kailera Therapeutics, Inc. | KLRA | 482931102 | $826.1K | 0.13% | 37,500 | SH |
| 23 | Disc Medicine, Inc. | IRON | 254604101 | $70.9K | 0.01% | 970 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-06-30 | 2026-08-14 | $642.6M | 23 | 0001104659-26-097133 |
| 2026-03-31 | 2026-05-15 | $460.3M | 17 | 0001104659-26-062467 |
| 2025-12-31 | 2026-02-17 | $330.8M | 12 | 0001104659-26-015412 |
| 2025-09-30 | 2025-11-14 | $258.9M | 12 | 0001104659-25-112509 |